ERV activates dsDNA and IFN responses, promotes type I IFN expression even in STING-deficient tumor cells, enhances natural and adaptive immunity, and improves the effectiveness of immunotherapy (Guo et al., 2022). This evidence concerns the gene IFNA1 and neoplasm.